title: Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats.
abstract: Antioxidant therapy may be useful in diseases with impaired oxidant-antioxidant balance such as pulmonary fibrosis. This study examines the effect of N-acetylcysteine (NAC) on bleomycin-induced lung fibrosis in rats. NAC (3 mmol x kg(-1); oral) was given daily from 1 week prior to a single intratracheal instillation of bleomycin (2.5 U x kg(-1)) or saline, until 14 days postinstillation. NAC partially decreased the augmented collagen deposition in bleomycin-exposed rats (hydroxyproline content was 4,354+/-386 and 3,416+/-326 microg x lung(-1) in vehicle-treated and NAC-treated rats, respectively; p < 0.05). The histological assessment using a semiquantitative score showed less collagen deposition and inflammatory cells in NAC-treated rats compared to those receiving bleomycin alone. NAC failed to inhibit the bleomycin-induced increases in lung wet weight and in cell counts and protein levels of bronchoalveolar lavage fluid, but significantly increased total glutathione and taurine levels in bronchoalveolar lavage fluid. These results indicate that oral N-acetylcysteine improves the pulmonary antioxidant protection and may be useful in reducing lung damage produced by bleomycin.
authors.affiliation: Dept of Pharmacology, University of València, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Cortijo
authors.forename: M
authors.initials: M
authors.lastname: Cerdá-Nicolás
authors.forename: A
authors.initials: A
authors.lastname: Serrano
authors.forename: G
authors.initials: G
authors.lastname: Bioque
authors.forename: J M
authors.initials: JM
authors.lastname: Estrela
authors.forename: F
authors.initials: F
authors.lastname: Santangelo
authors.forename: A
authors.initials: A
authors.lastname: Esteras
authors.forename: A
authors.initials: A
authors.lastname: Llombart-Bosch
authors.forename: E J
authors.initials: EJ
authors.lastname: Morcillo
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D001761:Bleomycin / Q000633:toxicity*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013654:Taurine / Q000378:metabolism
chemical_list: D016166:Free Radical Scavengers; D001761:Bleomycin; D013654:Taurine; D005978:Glutathione; D000111:Acetylcysteine